GenJet™ DNA In Vitro Tranfection Reagent for LNCap is pre-optimized for transfecting LNCap cells. LNCap cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells.
Refer to the following optimal transfection conditions for maximal transfection efficiency on LNCap cells. GenJet™ reagent, 1.0 ml, is sufficient for 300 to 600 transfections in 24 well plates or 50 to 100 transfections in 6 well plates.
Summary of Optimal Transfection Conditions: Confluence on the day of transfection Cell culture conditions
GenJet™ (µl) : DNA (µg) Ratio
Diluent for DNA and Transfection Reagent
Incubation Time to Form GenJet™/DNA Complex
Presence of Serum/Antibiotics during Transfection
Change Medium After Transfection
Maximal Efficiency
95% DMEM with 4.5 g/L glucose, 10% FBS 3:1
Serum-free DMEM with 4.5 g/L glucose
15 minutes at RT
Yes
No
48 hours
EGFP pEGFP-N3 (CMV promoter)
80%
Storage Condition Store at 4 °C. If stored properly, the product is stable for 12 months or longer
GenJet™ reagent is optimized for LNCap cells. LNCap cells were grown per ATCC recommended culture medium and transfected with pEGFP-N3 by GenJet™ (Ver. II). The efficiency was checked 48 hours post transfection Data Sheet